Atomo Diagnostics Ltd (ASX: AT1) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Atomo Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.18 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 639.20 million
Earnings per share -0.012
Dividend per share N/A
Year To Date Return 36.36%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Atomo Diagnostics Ltd (ASX: AT1)
    Latest News

    Investor with palm up and graphic illustration of asx small cap tech shares charts shooting from his hand
    Share Gainers

    These were the 5 top performing ASX shares in September

    Here are the top 5 for September.

    Read more »

    child holds swab and testing cup
    Share Market News

    Why the Atomo Diagnostics (ASX:AT1) share price has rallied 15% today

    Shares in the medical devices company are on the rise again. Here are the details

    Read more »

    Sonic Healthcare share price represented by man receiveing nasal swab from medical professional
    Share Gainers

    Why the Atomo Diagnostics (ASX:AT1) share price has soared 30% in a week

    The medical device company has had a terrific week.

    Read more »

    A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
    Earnings Results

    Atomo Diagnostics (ASX:AT1) share price sinks 8% on FY21 results

    Investors have been selling this medical device company's shares on Friday...

    Read more »

    Woman prepares to insert a swab in her nose to test for COVID-19 at home.
    Share Gainers

    Here's why the Atomo (ASX: AT1) share price flew 4% higher today

    The rapid COVID-19 test provider has been in the spotlight today.

    Read more »

    a man sits on a rocket propelled office chair and flies high above a city
    Share Market News

    The Atomo (ASX:AT1) share price has shot up 9%. Here's why

    The diagnostics company released its fourth-quarter business update today.

    Read more »

    Woman prepares to insert a swab in her nose to test for COVID-19 at home.
    Healthcare Shares

    Ellume is making news and these ASX shares are surging, again

    You can't buy shares in Ellume on the ASX, but here's the next best.

    Read more »

    Graphic showing yellow arrow above vertical columns indicating a rising share price
    Healthcare Shares

    Here's why the Atomo (ASX:AT1) share price is soaring 10%

    Personal rapid COVID-19 tests are in the news today, and the Atomo share price is benefitting.

    Read more »

    green arrow representing a rise in the share price
    Share Gainers

    Why Atomo, Metcash, Temple & Webster, & Woolworths are pushing higher

    These ASX shares have started the week strongly...

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    Share Market News

    Atomo Diagnostics (ASX:AT1) share price rockets 59% on COVID-19 test update

    This ASX share is starting the week with a bang...

    Read more »

    A fit man flexes his muscles, indicating a positive share price movement on the ASX market
    Healthcare Shares

    The Atomo (ASX:AT1) share price is soaring today. Here's why

    The Atomo (ASX: AT1) share price is up 4.8% today on news the company will be expanding access to its…

    Read more »

    a doctor looking up at question marks
    Share Fallers

    Why is the Atomo (ASX:AT1) share price trending downwards?

    The Atomo Diagnostics Limited (ASX: AT1) share price is down 16% since this time last month. What's been driving its…

    Read more »

    AT1 ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Atomo Diagnostics Ltd

    Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions

    AT1 Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.03 $0.00 0.00% 110,492 $0.03 $0.03 $0.03
    26 Mar 2024 $0.03 $0.00 0.00% 205,063 $0.03 $0.03 $0.03
    25 Mar 2024 $0.03 $0.00 0.00% 425,316 $0.03 $0.03 $0.03
    22 Mar 2024 $0.03 $0.00 0.00% 224,359 $0.03 $0.03 $0.03
    21 Mar 2024 $0.03 $0.00 0.00% 760,341 $0.03 $0.03 $0.03
    20 Mar 2024 $0.03 $0.00 0.00% 351,812 $0.03 $0.03 $0.03
    19 Mar 2024 $0.03 $0.00 0.00% 487,702 $0.03 $0.03 $0.03
    18 Mar 2024 $0.03 $0.00 0.00% 406,330 $0.03 $0.03 $0.03
    15 Mar 2024 $0.03 $0.00 0.00% 415,606 $0.03 $0.03 $0.03
    14 Mar 2024 $0.03 $0.00 0.00% 840,889 $0.03 $0.03 $0.03
    13 Mar 2024 $0.03 $0.00 0.00% 61,505 $0.03 $0.03 $0.03
    12 Mar 2024 $0.03 $0.00 0.00% 1,168,586 $0.03 $0.03 $0.03
    11 Mar 2024 $0.03 $0.00 0.00% 499,116 $0.03 $0.03 $0.03
    08 Mar 2024 $0.03 $0.00 0.00% 1,121,999 $0.03 $0.03 $0.03
    07 Mar 2024 $0.03 $0.00 0.00% 6,622,817 $0.03 $0.03 $0.03
    06 Mar 2024 $0.03 $0.00 0.00% 48,262,304 $0.03 $0.06 $0.03
    05 Mar 2024 $0.03 $0.00 0.00% 301,140 $0.03 $0.03 $0.03
    04 Mar 2024 $0.03 $0.00 0.00% 787,404 $0.03 $0.03 $0.03
    01 Mar 2024 $0.03 $0.00 0.00% 135 $0.03 $0.03 $0.03
    29 Feb 2024 $0.03 $0.00 0.00% 10,000 $0.03 $0.03 $0.03
    28 Feb 2024 $0.03 $0.00 0.00% 1,675 $0.03 $0.03 $0.03
    27 Feb 2024 $0.03 $0.00 0.00% 1,179,355 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Aug 2023 John Kelly Expiry 666,666 $19,999
    Options expired.
    11 Apr 2023 Curt LaBelle Expiry 1,200,000 $48,000
    Options expired.
    11 Apr 2023 John Keith Expiry 1,200,000 $48,000
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Paul Alexander Kasian Non-Executive Director
    Dr Kasian is an executive director with demonstrated achievement in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Chair of Risk Committee.
    Mr John Perry Keith Non-Executive ChairmanNon-Executive Director Dec 2011
    Mr Keith is one of the Managing Directors at BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign, and institutional clients across all areas of investment and institutional banking. He is Member of the Risk Committee.
    Mr John Michael Kelly FounderChief Executive OfficerManaging Director Apr 2010
    Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
    Ms Deborah Neff Non-Executive Director Sep 2021
    Ms Neff has spent most of her career building global businesses. As principal of DJN Consulting, LLC based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare start-up companies providing strategic business advice and mentoring to the executive management teams. Previously was CEO of Evanostics, LLC, Pathwork Diagnostics Inc, and COO at Complete Genomics following a 15-year career with Becton Dickinson, where she last served as President of BD Biosciences, a global business unit of the company. She is an Executive Trustee of the University of California, Davis Foundation and chairs the College of Biological Sciences Leadership Council at the University. He is also member of the Risk Committee.
    Dr Cheri Louise Walker Non-Executive Director Nov 2022
    Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher.
    Ms Sally McDow Company Secretary Mar 2024
    -
    William Souter Chief Financial Officer
    -
    Chandra Sukumar Chief Operating Officer
    -
    Sally McDow Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    GZ Family Holdings Pty Ltd 79,787,536 13.98%
    Dalraida Holdings Pty Limited 65,120,000 11.41%
    Global Health Investment Fund 64,811,280 11.35%
    Mr Xiaoyi Lin 11,500,000 2.01%
    Grand Challenges Canada 11,390,824 2.00%
    Liverbird Pty Ltd 10,931,653 1.91%
    ID&E Pty Ltd 9,032,248 1.58%
    Australia North Holdings Pty 8,100,000 1.42%
    Mark Andrew Smith 7,790,224 1.36%
    Mr Ian Fredrick Johnson 7,506,080 1.31%
    John Michael Kelly 7,370,248 1.29%
    Leo James Lynch 7,321,121 1.28%
    Ruth Karen Devney 5,626,408 0.99%
    Australia West Holdings Pty Ltd 5,250,000 0.92%
    Sokolov Pty Ltd 4,031,888 0.71%
    Rue Des Rocs Pty Ltd 3,800,000 0.67%
    H & L Management Pty Ltd 3,700,000 0.65%
    Citicorp Nominees Pty Limited 3,684,031 0.65%
    BNP PARIBAS NOMINEES PTY LTD 3,399,373 0.60%
    Miss Lisa Marie Mackenzie 3,351,968 0.59%

    Profile

    since

    Note